The acquisition strengthens BBI’s reagents antibodies portfolio.
The acquisition strengthens BBI’s reagents antibodies portfolio.
Source: BBI

Augmenting antibody services and assay development

Acquisition: BBI gains MBS

BBI Solutions (BBI), immunoassay developer and reagent supplier, acquired Maine Biotechnology Services Inc. (MBS) in July 2017, adding antibody development to the firm’s end to end assay development services. This also strengthens BBI’s reagents antibodies portfolio, providing a wide range of high quality biomarkers for infectious disease.

MBS, based in Portland, Maine (USA), has been a leader in custom antibody development services for over 27 years. The firm’s technical team bring unique hybridoma screening and characterisation protocols to BBI clients. ‘Through this acquisition, BBI Solutions now has the opportunity to partner with IVD development customers earlier in their R&D process, delivering antibodies screened and selected specifically for their end use applications,’ BBI reports.

Customer support will aslo be available through antigen review, cGMP antibody production, purification, and characterisation. ‘Availability of in-house antibody capabilities will be particularly advantageous to lateral flow development customers who can now work with BBI from planning a reagent strategy, through to final diagnostic production,’ the firm adds. ‘Having one comprehensive provider will allow customers to seamlessly identify and prevent antibody performance risks, both during development and over the lifetime of the immunoassay kit manufacturing.’

Products added to BBI Solutions from MBS include antibodies recognising myeloperoxidase, cortisol, osteopontin, PEG, Ig controls, His-tag, norovirus, rotavirus, adenovirus, chikungunya virus, zika virus, and dengue fever.

Go to: www.bbisolutions.com, or visit www.mainebiotechnology.com to read more about BBI antibody development services.


BBI is at MEDICA

Hall 3A. Stand 3AB02-1

12.11.2017

Read all latest stories

Related articles

ECCMID 2015

Curetis launches next-generation pneumonia application

Curetis AG, a developer of next-level molecular diagnostic solutions, announced the successful completion of the clinical and analytical CE performance evaluation of its next-generation Unyvero P55…

Shimadzu Europa 50th anniversary

Mass spectrometry and ever more…

As Shimadzu celebrates its 50th anniversary in Europe, we spoke with Stéphane Moreau, Manager of LC-MS & Life Sciences at the Marketing Europe/Analytical Business Unit of Shimadzu Europa GmbH,…

Evolving technique

Flow cytometry rises to new challenges

Flow cytometry has proved an invaluable diagnostic tool for leukaemia and lymphoma for almost three decades. Now, however, this is evolving in applications to seek out residual disease in cases and…

Related products

Immunochemistry

Beckman Coulter - Anti-Mullerian Hormone (AMH)

Beckman Coulter, Inc.

Immunoassays

FUJIFILM Wako - μTASWako i30

Wako Chemicals GmbH

LIS, Middleware, POCT

i-SOLUTIONS Health - LabCentre

i-SOLUTIONS Health GmbH

LIS, Middleware, POCT

Medat - Laboratory Information System

Medat Computer-Systeme GmbH